Pioneer of RNA-interference (RNAi) drugs, selling Onpattro/Amvuttra for ATTR amyloidosis and other genetic diseases.
Pioneer of RNA-interference (RNAi) drugs, selling Onpattro/Amvuttra for ATTR amyloidosis and other genetic diseases.
Sells its own RNAi medicines, led by Amvuttra for ATTR amyloidosis, a buildup of misfolded protein that damages nerves and the heart, and has built its income by widening that drug's approved uses. Its technology is a platform that can be aimed at new targets, which is why it also has partnerships with larger drugmakers such as Roche and Regeneron.
Moat: wide (IP / patents, process know-how). Founding RNAi patents and manufacturing know-how give a multi-year head start over followers.
Headquarters: Cambridge, Massachusetts, United States · Founded: 2002 · Employees: 2,500
Size Alnylam Pharmaceuticals (ALNY) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $20.0B, the 489th largest of 3,085 United States companies the cockpit tracks. Shares closed at $149.40 on 18 Nov 2026.
Performance Over six months the shares fell 50.0%, against +5.2% for the median peer and -2.2% for the United States market (cap-weighted) — lowest of 21 in its peer set.
Growth Revenue grew 56.2% over the last twelve months (peer median +29.3%); the operating margin is 19.5% (peer median 20.2%).
Valuation It trades at 21.2× forward earnings against a peer median of 24.1× (8th cheapest of 18).
Price implies For today's price to make sense, revenue must grow about 1% a year for seven years (Req g). Recent delivered growth is +50%, so the hurdle is -49 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 18.7 points above its cost of capital (6.9% WACC).
Credit Alnylam Pharmaceuticals has 2 bonds outstanding ($1.06B).
Short interest Short interest is 4.1% of the free float (30 Oct 2026).
Next results Next results expected around 18 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $5.01B | $3.71B | $2.25B | $1.83B | $1.04B |
| Revenue growth | — | +65% | +23% | +76% | — |
| Gross profit | $3.87B | $3.03B | $1.92B | $1.52B | $869M |
| EBITDA | $1.03B | $557M | -$120M | -$228M | -$741M |
| Net income | $2.72B | $314M | -$278M | -$440M | -$1.13B |
| Free cash flow | $752M | $465M | -$42.6M | $41.9M | -$613M |
| Capital expenditure | $150M | $58.7M | $34.3M | $62.2M | $72.1M |
| Total debt | $3.00B | $2.97B | $2.74B | $2.68B | $2.61B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Alnylam Pharmaceuticals ALNY | $20.0B | -50% | +56% | 20% | 21.2× | 0.5% |
| Ionis Pharmaceuticals IONS | $4.56B | -64% | -1% | -59% | n/a | n/a |
| Pfizer PFE | $160B | +9% | +1% | 26% | 9.9× | -4.3% |
| BridgeBio Pharma BBIO | $15.2B | +14% | +167% | -37% | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ALNY | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -35.2% | +6.1% | lowest of 21 |
| 6-month return | -50.0% | +5.2% | lowest of 21 |
| Distance from 52-week high | -68.9% | -9.1% | lowest of 21 |
| Revenue growth (TTM) | +56.2% | +29.3% | 6th highest of 21 |
| Operating margin | 19.5% | 20.2% | 11th highest of 21 |
| Forward P/E | 21.2× | 24.1× | 8th cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | 0.5% | 11.2% | 8th least demanding of 18 |
| Growth delivered (Del g) | +49.8% | +12.5% | 3rd highest of 18 |
| Hurdle (Req g minus delivered) | -49.2 pp | -10.8 pp | 3rd least demanding of 18 |
| ROIC minus cost of capital | +18.7 pp | +7.2 pp | 7th highest of 21 |
| EV / EBITDA | 18.8× | 22.4× | 8th cheapest of 16 |
| Net debt / EBITDA | -0.6× | -0.0× | 7th least indebted of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Alnylam Pharmaceuticals ALNY | United States | $20.0B | -50% | +56% | 20% | 21.2× | 0.5% | +49.8% |
| Innovent Biologics 1801.HK | Hong Kong | $18.9B | +4% | +43% | 17% | 52.3× | 11.6% | +26.8% |
| Torrent Pharmaceuticals TORNTPHARM.NS | India | $18.8B | +3% | +42% | 22% | 70.2× | 37.6% | +11.3% |
| Sigma Healthcare SIG.AX | Australia | $22.4B | +2% | +209% | 9% | 38.4× | 28.9% | +26.1% |
| Shionogi & 4507.T | Japan | $17.6B | +3% | +46% | 29% | 11.8× | 0.2% | +11.0% |
| Viatris VTRS | United States | $23.3B | +23% | +5% | 11% | 7.5× | 11.2% | +3.7% |
| Ascendis Pharma A/S ASND | United States | $16.9B | +12% | +94% | 18% | 28.0× | 19.2% | +152.4% |
| Incyte INCY | United States | $24.0B | +21% | +25% | 12% | 15.1× | 14.2% | +14.0% |
| Exelixis EXEL | United States | $16.7B | +37% | +9% | 40% | 17.7× | -3.8% | +18.6% |
| Swedish Orphan Biovitrum SOBI.ST | Sweden | $16.1B | +6% | +15% | 30% | 24.1× | -2.1% | +13.1% |
| Jazz Pharmaceuticals Public JAZZ | United States | $15.9B | +4% | +13% | 25% | 9.3× | -2.8% | +12.5% |
| Hansoh Pharma 3692.HK | Hong Kong | $25.3B | -3% | +25% | 38% | 25.8× | 7.9% | +10.8% |
| Orion ORNAV.HE | Finland | $15.7B | +41% | +34% | 38% | 23.6× | -6.2% | +11.7% |
| Insmed INSM | United States | $26.3B | +3% | +240% | -42% | n/a | n/a | n/a |
| PharmaEssentia 6446.TW | Taiwan | $15.0B | +67% | +78% | 40% | 31.9× | 23.7% | +94.8% |
| Yunnan Baiyao 000538.SZ | China | $15.0B | +11% | +5% | 11% | 18.3× | -0.2% | +4.7% |
| Sichuan Biokin Pharmaceutical 688506.SS | China | $14.9B | -7% | +14% | -43% | n/a | n/a | n/a |
| Ipsen IPN.PA | France | $14.8B | +1% | +14% | 30% | 10.8× | -6.7% | +7.2% |
| Roivant Sciences ROIV | United States | $28.1B | +20% | +102% | -3,234% | n/a | n/a | n/a |
| Laurus Labs LAURUSLABS.NS | India | $13.4B | +73% | +23% | 24% | 76.4× | 51.2% | +7.3% |
| Sichuan Kelun-Biotech Biopharmaceutical 6990.HK | Hong Kong | $13.0B | -1% | +44% | -38% | 1,176.1× | 55.3% | +33.6% |
Alnylam Pharmaceuticals has 2 bonds outstanding with $1.06B face value.